Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Irritable Bowel Syndrome I: Introduction01:17

Irritable Bowel Syndrome I: Introduction

263
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
263
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

159
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
159
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

205
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
205
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

122
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
122
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

328
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
328
Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

400
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
400

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Clinicopathological and prognostic significance of mucin signatures in lower gastrointestinal cancer-a systematic review and meta-analysis.

British journal of cancer·2025
Same author

Clinical Significance of Mucin Signatures in Inflammatory Bowel Diseases: A Systematic Review of Their Expression Patterns, Polymorphisms, and Post-translational Modifications.

Inflammatory bowel diseases·2025
Same author

Functional implications of respiratory syncytial virus F sequence variability: a comparative analysis using contemporary RSV isolates.

mSphere·2025
Same author

Comparison of different microbiome analysis pipelines to validate their reproducibility of gastric mucosal microbiome composition.

mSystems·2025
Same author

The Intestinal Mucin Isoform Landscape Reveals Region-Specific Biomarker Panels for Inflammatory Bowel Disease Patient Stratification.

Journal of Crohn's & colitis·2024
Same author

IL-22-Activated <i>MUC13</i> Impacts on Colonic Barrier Function through JAK1/STAT3, SNAI1/ZEB1 and ROCK2/MAPK Signaling.

Cells·2023

相关实验视频

Updated: Jun 14, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.4K

炎症性肠病中的微生物组

Aranzazu Jauregui-Amezaga1,2, Annemieke Smet2

  • 1Department of Gastroenterology and Hepatology, University Hospital Antwerp, 2650 Edegem, Belgium.

Journal of clinical medicine
|August 29, 2024
PubMed
概括

炎症性肠病 (IBD) 管理面临着当前免疫抑制剂的挑战. 针对肠道微生物组的新疗法对IBD有希望,但它们的长期安全性需要进一步调查.

科学领域:

  • 胃肠病学 胃肠病学
  • 免疫学 免疫学 免疫学
  • 微生物学 微生物学

背景情况:

  • 目前的炎症性肠病 (IBD) 治疗方法长期有效性有限,副作用很大.
  • IBD是一种多因素的疾病,涉及遗传易感性和不适当的免疫反应,肠道微生物群发挥着关键作用.
  • 由改变的微生物组成和减少的多样性特征的肠道失生症与IBD的发病有关.

研究的目的:

  • 审查肠道微生物组在IBD中的作用.
  • 探索针对肠道微生物组进行IBD管理的新型治疗策略.
  • 要突出考虑病毒和真菌的重要性,除了细菌,在IBD相关的失生症.

主要方法:

  • 关于IBD病理生理学和治疗的当前文献的综述.
  • 对研究IBD患者肠道微生物组的研究进行分析.
  • 检查调节肠道微生物组的新兴疗法.

主要成果:

  • 肠道疾病,包括细菌,病毒和真菌的变化,是IBD的重要因素.
  • 虽然已注意到微生物组与生物制剂的变化,但它们作为生物标记物的有用性尚不确定.
  • 针对肠道微生物组的疗法有可能用于IBD治疗.
关键词:
克罗恩氏病是什么 克罗恩氏病是什么生物膜是一种生物膜.生物标志物生物标志物这种疾病叫做dysbiosis.我们的微生物群.性结肠炎是一种

更多相关视频

Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.0K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K

相关实验视频

Last Updated: Jun 14, 2025

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
08:24

Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach

Published on: May 2, 2018

19.4K
Chronic Salmonella Infection Induced Intestinal Fibrosis
08:40

Chronic Salmonella Infection Induced Intestinal Fibrosis

Published on: September 22, 2019

7.0K
Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
07:34

Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice

Published on: December 16, 2021

2.5K

结论:

  • 调节肠道微生物组为未来IBD疗法提供了一个有希望的途径.
  • 需要进一步的研究,以了解向微生物组的IBD治疗的安全性和长期影响.